NK1 Receptor Stimulation Causes Contraction and Inositol Phosphate Increase in Medium-size Human Isolated Bronchi
- 1 April 2001
- journal article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 163 (5) , 1206-1211
- https://doi.org/10.1164/ajrccm.163.5.2002079
Abstract
Although contraction of human isolated bronchi is mediated mainly by tachykinin NK2 receptors, NK1 receptors, via prostanoid release, contract small-size (approximately 1 mm in diameter) bronchi. Here, we have investigated the presence and biological responses of NK1 receptors in medium-size (2-5 mm in diameter) human isolated bronchi. Specific staining was seen in bronchial sections with an antibody directed against the human NK1 receptor. The selective NK1 receptor agonist, [Sar(9), Met(O2)(11)]SP, contracted about 60% of human isolated bronchial rings. This effect was reduced by two different NK1 receptor antagonists, CP-99,994 and SR 140333. Contraction induced by [Sar(9), Met(O2)(11)]SP was independent of acetylcholine and histamine release and epithelium removal, and was not affected by nitric oxide synthase and cyclooxygenase (COX) inhibition. [Sar(9), Met(O2)(11)]SP increased inositol phosphate (IP) levels, and SR 140333 blocked this increase, in segments of medium- and small-size (approximately 1 mm in diameter) human bronchi. COX inhibition blocked the IP increase induced by [Sar(9), Met(O2)(11)]SP in small-size, but not in medium-size, bronchi. NK1 receptors mediated bronchoconstriction in a large proportion of medium-size human bronchi. Unlike small-size bronchi this effect is independent of prostanoid release, and the results are suggestive of a direct activation of smooth muscle receptors and IP release.Keywords
This publication has 22 references indexed in Scilit:
- In vitro and in vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK1 receptor antagonistPublished by Elsevier ,2002
- Tachykinins and kinins in airway allergyExpert Opinion on Investigational Drugs, 1999
- In vitro and in vivo pharmacology of S 16474, a novel dual tachykinin NK1 and NK2 receptor antagonistEuropean Journal of Pharmacology, 1995
- Tachykinins, sensory nerves, and asthma—an overviewCanadian Journal of Physiology and Pharmacology, 1995
- Tachykinin NK1 and NK2 receptors mediate the non‐cholinergic bronchospastic response to capsaicin and vagal stimulation in guinea‐pigsJournal of Autonomic Pharmacology, 1995
- Sensory neuropeptide release by bradykinin: mechanisms and pathophysiological implicationsRegulatory Peptides, 1993
- The pharmacology of the efferent function of sensory nerves.Journal of Autonomic Pharmacology, 1991
- Modulation of neurogenic inflammation: novel approaches to inflammatory diseaseTrends in Pharmacological Sciences, 1990
- The glucose oxidase-DAB-nickel method in peroxidase histochemistry of the nervous systemNeuroscience Letters, 1988
- Effect of inhaled substance P and neurokinin A on the airways of normal and asthmatic subjects.Thorax, 1987